In a bid to unravel the complexities of Non-Alcoholic Fatty Liver Disease (NAFLD), the NIHR NAFLD BioResource has recruited its 3000th participant at the Royal Blackburn Teaching Hospital. This marks a big step forward in the understanding and treatment of this prevalent and often overlooked health concern.
We are delighted to have supported the NAFLD BioResource to meet this important milestone – with other 3000 patients now recruited nationally, alongside other large international cohorts, the NAFLD BioResource will help deliver much needed research into this common liver disease.
– Professor Quentin Anstee, Principal Investigator, Newcastle University
The journey to 3,000 patients is a testament to the collaboration that defines the NAFLD BioResource – from the hubs in Birmingham, Newcastle and Nottingham, to the researchers, clinicians, and patients from across England that have joined forces to build a diverse cohort that reflects the multifaceted nature of NAFLD. The 3,000 participants represent a wealth of data for investigating the various factors contributing to the disease, from genetic predispositions to lifestyle influences.
One of the key strengths of the NAFLD BioResource lies in its ability to bridge the gap between research and real-world impact. By actively involving patients in the research process, the project ensures that the outcomes are meaningful and applicable to those directly affected by NAFLD.
As we celebrate the 3,000-patient milestone, it’s essential to acknowledge the efforts of everyone involved – the patients who generously contribute their data, the healthcare professionals and the researchers translating findings into improvements in patient care.
What is next for NAFLD?
As the NAFLD BioResource looks towards the future, the journey is far from over. The 3,000-patient milestone is a remarkable achievement, but with continued collaboration and a dedication to advancing our understanding of NAFLD, the BioResource hopes to make further contributions to the field of liver health through supporting studies and clinical trials.